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CLINICAL CASE OF A PATIENT UNDERGOING 
RADIUM-223 TREATMENT FOLLOWING TREATMENT 
WITH ABIRATERONE ACETATE AND ENZALUTAMIDE
M.E. Jiménez Romero*, S. Díez Farto, J.C. Navarro Serrato, E. Canelón Castillo, I. Revelo Cadena
Urological Department of the University Hospital of Puerto Real, Cádiz 11510, Spain
Objective: Over the last decade, significant advances have been made in the development of therapies for patients with metastatic 
castration-resistant prostate cancer. Abiraterone and enzalutamide were approved as treatments based on data supporting improved 
overall survival compared to placebo. Radium-223 became the first approved radiopharmaceutical which decreased skeletal-related 
events, palliated pain, and showed improved overall survival in symptomatic patients with castration-resistant prostate cancer 
and bone metastasis only. Materials and Methods: We present the case of an eighty-two year old man with metastatic castration-
resistant prostate cancer who was treated with sequential therapy (abiraterone — enzalutamide — radium 223). The sequencing 
and treatment used for our patient was viable because of his clinical characteristics, which have allowed for longer survival time with 
an acceptable quality of life. These actions must be agreed on by the Multidisciplinary Tumour Board, in order to optimize the use 
of available courses of treatment. Results: The treatment of these patients is changing rapidly, but many questions remain regarding 
the optimal sequencing of the available drugs. Sequential or concomitant use of the next generation hormonal agents — abiraterone 
and enzalutamide — cannot currently be recommended. Data regarding the safety of concomitant abiraterone, enzalutamide or de-
nosumab with radium-223 is reassuring and timely. However, we cannot advocate the general use of combined radium-223 therapy 
at this time, irrespective of prior therapy. Conclusion: A better understanding of active mechanisms, the genetic characteristics 
of each metastatic castration-resistant prostate cancer and the development of new prognostic and predictive biomarkers will help 
determine sequencing or different combination treatments for each individual patient.
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Prostate cancer (PC) is the second most com-
monly diagnosed cancer, and is the fifth leading cause 
of cancer death in men [1]. Most of the men who are 
diagnosed with PC present with apparent localized 
disease. Despite initial treatment, some of these 
men will go on to have disease progression, firstly 
presenting with biochemical recurrence even if there 
is no clinical or radiographic evidence of disease. 
Then, many continue to progress and develop distant 
metastatic disease. Other patients present with meta-
static disease de novo at the time of the first diagnosis. 
Treatment for advanced disease usually begins with 
androgen deprivation therapy. The majority of cases 
initially respond to androgen-deprivation, progress-
ing towards castration-resistance. Most patients will 
develop metastases — bone metastasis being the 
most frequently observed — and an independent 
poor prognostic factor [2]. Until recently, the only 
treatment for these patients that had proven success-
ful in increasing overall survival rates was docetaxel. 
In the last decade, significant progress has been made 
in the development of new agents against metastatic 
castration-resistant prostate cancer (mCRPC) [3]. 
Treatments based on abiraterone acetate (AA) [4] 
and enzalutamide (ENZ) [5] were approved after the 
publication of data which demonstrated an increase 
of the overall survival rates, when compared to a pla-
cebo group, simultaneously reducing the time period 
to the first skeletal-related event (SRE) and — in the 
case of AA treatment — reducing pain. In the last 
few years, the high efficiency and low toxicity of both 
treatments, coupled with the experience acquired, 
have changed the conditions of our patients suffering 
from mCRPC. Furthermore, the therapeutic algorithm 
of these patients has changed recently with the intro-
duction of radium-223, the first approved radiophar-
maceutical which has shown an improvement in pain 
control, reduced SREs and increased survival rates 
in symptomatic or minimally symptomatic patients with 
mCRPC and bone metastasis.
MATERIALS AND METHODS
Eighty-two year old male with existing history 
of high blood pressure, being treated with enalapril; 
and of hypercholesterolemia, being treated with sim-
vastatin. Ex-smoker of 10 cigarettes a day for many 
years. In August 2009, at 75 years of age, the patient 
was diagnosed with a sigmoid colon adenocarcinoma 
(stage IIA) requiring surgery (laparoscopic sigmoidec-
tomy) and adjuvant chemotherapy (since then, Onco-
logy has carried out several follow-up consultations 
with no recurrence).
In May 2010, the patient attended our practice 
following a referral from Oncology for a symptomato-
logy assessment of the lower urinary tract, present-
ing with high prostate-specific antigen (PSA) levels 
(24.20 ng/ml). The rectal examination revealed a pros-
tate of increased size and mass. A transrectal prostate 
biopsy was carried out, the results of which confirmed 
a prostate adenocarcinoma with a Gleason score 
of 8 (4 + 4, bilateral) with marked perineural invasion 
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and extension to the prostate tissue on both lobes. The 
extension study, carried out by means of computerized 
tomography (CT), revealed an extracapsular exten-
sion, but no visceral or lymph node metastases. The 
bone scan provided findings consistent with metastatic 
bone disease (in the right sacroiliac region; clinical 
stage cT3b N0 M1b).
Given these results and a PC diagnosis at an advanced 
metastatic stage, continuous androgen- deprivation 
therapy was initiated (six-monthly luteinizing-hor-
mone releasing-hormone agonist) + zoledronic acid 
(4 mg administered intravenously on a monthly basis, 
for 18 months) + calcium and vitamin D supplements. 
Initially, monitoring took place at a follow-up visit three 
months later and every six months after that.
A course of monotherapy with a six-monthly 
agonist was initiated in July 2010, prompting a rapid 
biochemical response and a reduction of PSA lev-
els, which reached their lowest point in December 
2011 at 0.40 ng/ml. Testosterone remained at cas-
tration level. In March 2013, PSA levels increased 
up to 2.78 ng/ml, which prompted further hormonal 
treatment yielding a biochemical response lasting 
up to August 2013 (PSA levels of 5.78 ng/ml). Conse-
quently, a new radiological assessment with a CT scan 
was requested, which ruled out visceral metastases, 
while the bone scan revealed new affected areas in the 
left sacroiliac region and on the right ischium (Fig. 1). 
Following the diagnosis of mCRPC, the patient was ex-
amined in a specific consultation which included a full 
evaluation. The response to the 35-month androgen-
deprivation therapy presented a score of 0 according 
to the ECOG scale; the patient was asymptomatic and 
did not require analgesia (0, according to the brief 
pain inventory — short form), although the patient did 
complain of mild asthenia.
Fig. 1. Bone scan revealing affected areas in the left sacroiliac 
region and right ischium
In light of all these considerations, treatment with 
AA (four 250 mg capsules a day + 10 mg predni-
sone daily) was initiated in September 2013. At the 
same time, it was decided that treatment for bone 
metastasis be resumed by prescribing denosumab 
(120 mg as a monthly subcutaneous injection). In June 
2014, after 9 months of treatment, PSA levels reached 
their lowest point, at 0.25 ng/ml, with alkaline phos-
phatase levels remaining within normal limits.
The patient remained stable, without clinical or ana-
lytical changes, no side effects, and with quarterly 
check-ups (including a new CT scan and a bone scan 
15 months after the beginning of treatment) until Au-
gust 2015. At that time, PSA levels, which had remained 
stable thus far, increased to 8.30 ng/ml and alkaline 
phosphatase levels increased to 154.5 U/l. A mild clini-
cal deterioration of the patient’s health was observed 
and first-line analgesic treatment (paracetamol) was 
prescribed with good results.
At the beginning of December 2015, after 27 months 
of treatment, PSA levels were 30.43 ng/ml, with 
significant asthenia and pain controlled by means 
of the prescribed analgesic. Alkaline phosphatase 
levels reached 342 U/l and a new extension study with 
a CT scan and bone scan demonstrated advanced 
bone metastasis (Fig. 2, 3).
Fig. 2. CT scan showing advancement of the bone metastasis
In February 2016, AA was suspended and it was 
decided that treatment consisting of ENZ (four 
40 mg capsules daily) be initiated. The patient pre-
sented with more acute asthenia and worsening hip 
pain, which necessitated second-line analgesic treat-
ment (tramadol). Two months into the ENZ treatment, 
and due to the limited clinical benefits observed — 
associated with a reduced quality of life due mainly 
to pain — this treatment was suspended and new ra-
diological tests were requested, with a view to starting 
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treatment based on radium-223. The CT scan of the 
chest, abdomen and pelvis displayed advancement 
of the bone meta stasis without visceral or lymph node 
disease (Fig. 4). A basal haematological evaluation 
was carried out including an absolute neutrophil and 
platelet count, as well as an assessment of hepatic 
and renal function, which did not contraindicate the 
start of treatment. In this context of symptomatic 
bone disease without visceral or lymph node dis-
orders, it was decided that treatment based on ra-
dium-223 be initiated.
Fig. 4. Chest, abdomen and pelvis CT scan; advanced bone 
metastasis; lack of visceral or lymph node metastases
Close cooperation with the Nuclear Medicine Ser-
vice was established, and a joint follow-up schedule 
was agreed upon, consisting of a full blood test before 
each dose of radium-223. The patient completed six 
full one-month cycles of treatment. He received the 
first dose in May 2016, having previously suspended 
treatment with calcium and vitamin D supplements. 
Coinciding with the administration of the first dose, the 
patient reported a slight increase of polyostotic bone 
pain, corresponding to a flare effect described in the 
pivotal study (ALSYMPCA) [6]. Four weeks later, fol-
lowing the administration of the second dose, the blood 
tests detected an increase of PSA levels and a reduction 
of alkaline phosphatase levels, showing pain relief and 
good tolerance towards the treatment. Therefore, the 
therapeutic programme was continued. Before the third 
dose, the patient suffered from anaemia (Hb = 8.2 g/dl) 
which prompted the decision to carry out two transfu-
sions of red blood cell concentrates. During the rest 
of the dosage, the patient reported two isolated cases 
of diarrhoea. Altogether, the patient showed very con-
siderable improvement in terms of pain relief and did not 
require further analgesic treatment. Notwithstanding, 
PSA levels increased up to 421 ng/ml, at the date of the 
final dose, whereas alkaline phosphatase levels fell con-
siderably (187.7 U/l) without returning to normal levels.
In November 2016, a reassessment was carried 
out after the course of treatment had been completed 
which presented a mild clinical deterioration. The patient 
continued to take a six-monthly agonist with a calcium 
and vitamin D supplement, which was re- established 
following the final dose of the radiopharmaceutical. 
PSA levels remained stable (435 ng/ml) and alkaline 
phosphatase levels increased up to 545 U/l.
At the end of December 2016, the bone and 
CT scans displayed further progression of the bone 
metastasis (Fig. 5). The patient was re-admitted twice 
with anaemia, requiring a blood transfusion. At the 
end of February 2017, they were admitted again for 
anaemia, requiring a transfusion (Hb = 6.7 g/dl), and 
predominantly evening asthenia with bone pain con-
trolled by means of a second-grade analgesic treatment 
(tramadol). The monthly follow-up appointments were 
continued (for the control of the anaemia and the pain).
Fig. 5. Diffuse bone metastasis on bone scintigraphy
Fig. 3. New bone scan showing advancement of the bone 
metastasis
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Eighty-three months after the PC diagnosis and 
as of March 2017, the patient has an acceptable quality 
of life. Following completion of the treatment, we have 
observed marrow toxicity and requested transfusions 
every four to five weeks in order to treat grade 3 anae-
mia. The patient reports general bone pain which cur-
rently require third-line analgesic treatment (morphic 
drugs). Considering all the above, it was decided that 
systemic treatment with chemotherapy be ruled out.
DISCUSSION
The emergence of these new highly effective 
therapies poses a significant clinical challenge; 
in this regard, the current debate is trying to posi-
tion radium-223 within the therapeutic algorithm 
of mCRPC [7]. The question is whether to administer 
it before, during the course of the disease, concomi-
tant with new hormonal therapies or, on the contrary, 
to wait until the patient progresses to a treatment with 
chemotherapy, ENZ or AA. Furthermore, if the op-
tion chosen is to combine it with AA or ENZ, it would 
be essential to know the efficacy and safety of this 
combination.
Sequencing is being trialled with the hope of ob-
taining a cumulative benefit for survival. In the pre-che-
motherapy setting, the information currently available 
is based on retrospective studies of very small series 
and a highly heterogeneous patient population [8]. 
However, the efficacy of this practice has not been 
backed up by data derived from clinical trials, and 
evidence from potential cross-resistance reinforces 
the debate surrounding the best sequence to use in or-
der to maximize the benefits. This situation becomes 
more difficult given evidence showing the possibility 
of administering hormonal agents in patients who 
have not undergone chemotherapy and administering 
new chemotherapeutic agents in patients sensitive 
to hormone treatment. Thus, a thorough study is re-
quired, including the characteristics of each patient 
and their disease, as well as safety profiles and the 
efficiency of each drug, in order to be able to find 
the best treatment sequencing for each individual, 
whether as monotherapy or as in combination [9, 10]. 
For example, if a patient with an asymptomatic case 
of mCRPC undergoing concomitant treatment with 
docetaxel and radium-223 showed progression to the 
bone, the possible options available later in terms 
of bone pain treatment are drastically reduced. Defini-
tive data will be published soon regarding the safety 
and efficiency of re-treatment with radium-223 in pa-
tients who have previously been administered with 
docetaxel. These results may serve to clarify some 
of our doubts.
In terms of a combination of treatments, Saad 
et al. [11] have recently published a phase 3b trial ana-
lyzing the safety and efficiency of radium-223 and other 
concomitant therapies in patients with CPRC. It includes 
a total of 606 Caucasian symptomatic or asymptomatic 
males, over 18 years old, with a prevalence of bone 
disease and at least two bone metastases. Patients 
with visceral disease were excluded but not those with 
lymph node metastases. Patients were to receive six 
intravenous injections of radium-223 every four weeks 
in 50 kBq/kg doses. Other concomitant therapies 
were permitted, such as AA, ENZ or denosumab. The 
primary endpoints of the study were overall survival 
and safety. Only 58% of patients were administered 
with the six injections of radium-223. After a median 
follow-up period of 7.5 months, the authors reported 
an improvement of overall survival rates in patients 
taking radium-223 in combination with either ABI, 
ENZ, ENZ and ABI, or denosumab. The same benefit 
was not observed in patients who were administered 
with radium-223 and bisphosphonates. Tolerance 
for the treatment was good with only 21% of patients 
suspending the treatment due to side effects. The 
most common side effect was grade 3 anaemia (12%) 
and grade 3–4 combined cytopenia (anaemia, throm-
bocytopaenia, leukopenia and neutropenia), which 
were observed in 20% of subjects. Given the relatively 
short follow-up period (7.5 months), the possibility 
of delayed or persistent marrow toxicity under these 
combinations is still to be determined.
We believe that the number of radium-223 doses 
and infusions needed in this combined therapy could 
be lower than those currently approved for mono-
therapy. At the same time, it is yet to be determined 
whether this combination could lead to the occurrence 
of a form of PC which is highly resistant to the treat-
ment, given the potential biological alteration of the 
tumor or the development of resistance (AR-V7) [12].
Our patient comfortably met the inclusion criteria 
set up for the pivotal trial (ALSYMPCA) [1]. Following 
a good response to AA treatment, the sequential ENZ 
therapy did not prove to be effective, leading to rapid 
clinical, biochemical and radiological progression. 
After this, the patient began radium-223 treatment with 
a good clinical response to pain, which was reduced 
after the first dose. Furthermore, no bone-related 
events arose, which was of considerable benefit to the 
patient’s quality of life. Moreover, the side effect profile 
during the treatment was acceptable and easily man-
aged by the clinician.
CONCLUSIONS
Although treatment for mCRPC is changing rapidly, 
there are still many open questions regarding the opti-
mal treatment sequence. The sequential or combined 
use of AA and ENZ is currently not recommended. 
We chose this particular sequencing for the patient 
because of his characteristics. At said time, there was 
little evidence available regarding the AA — ENZ Se-
quencing. Normally, unltil solid evidence is available, 
this type of sequencing not apply on our patients.
Radium-223 is a therapeutic option for mCRPC pa-
tients, both as an initial treatment or in cases of resis-
tance towards other treatments, as its action mecha-
nism suggests few chances of crossed resistance 
to other agents. The results obtained demonstrate that 
radium-223 can be safely combined with AA or ENZ, 
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which are standard treatments for mCRPC patients — 
as has been proven by this particular case — with little 
and manageable side effects.
At the same time, these results can be applied 
to asymptomatic patients, who were not analyzed 
as part of the ALSYMPCA pivotal study. In our opinion, 
radium-223 should feature in the early stages of our 
therapeutic algorithm, and be administered before 
patients develop extra-osseous disease.
The emergence of new therapies against mCRPC 
is expected soon, which means that the challenge 
will be to learn how to combine and sequence these 
agents. Ongoing studies, along with the additional 
information expected from the studied biomarkers, 
will help us refine our selection of suitable treat-
ments [13].
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